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Zusammenfassung
Hintergrund: Ewing-Tumoren (ET) treten selten bei Pa-
tienten im Alter von über 40 Jahren auf. Entsprechend li-
mitiert sind die Daten zu Klinik, Therapie und Überleben
bei diesen Patienten. Patienten und Methoden: Der re-
trospektiven Analyse lagen Daten von 47 Patienten zu-
grunde, bei denen im Alter von über 40 Jahren die Dia-
gnose eines ET gestellt wurde. Medianes Alter bei Dia-
gnosestellung war 47,7 Jahre (Range, 40–68,6 Jahre). Die
Behandlung erfolgte nach den Studien EICESS 92 oder
EURO-E.W.I.N.G. 99. Ergebnisse: Der Nachbeobach-
tungszeitraum betrug 2,23 Jahre (Range, 0,35–12,92
Jahre) nach Diagnosestellung. Bei 72,3% der Patienten
wurde eine lokalisierte Erkrankung diagnostiziert, 27,7%
hatten primäre Metastasen. Gutes klinisches Ansprechen
auf die Induktionstherapie zeigten 55% (n = 20) und 73%
der Patienten zeigten gutes histologisches Ansprechen.
Das ereignisfreie Überleben (EFS) lag bei 0,77 nach
einem und 0,50 nach 3 Jahren (n = 44). Schlussfolgerun-
gen: Bei adäquater multimodaler Therapie sind die Er-
gebnisse für Patienten über 40 Jahre in Bezug auf das
Überleben vergleichbar mit denen junger Patienten. Spe-
zifische altersangepasste Behandlungsprotokolle sind
nicht etabliert. Patienten sollten daher in die aktiven
internationalen Studien eingebracht werden, um, sofern
notwendig, die Behandlung an eine geringere Toleranz
und Komorbiditäten anzupassen.
Key Words
Adults · Chemotherapy · Ewing’s tumor · Radiotherapy ·
Surgery
Summary
Background: Ewing’s tumors (ET) are rare in patients
over the age of 40 years. Published data on presentation,
treatment, and clinical outcome are limited. Patients and
Methods: We present a retrospective analysis of data
from 47 patients in this age group diagnosed with ET and
enrolled in the 2 consecutive trials, EICESS 92 and
EURO-E.W.I.N.G. 99. The median age at diagnosis was
47.7 years (range, 40–68.6 years). Results: The median
follow-up was 2.23 years from diagnosis (range,
0.35–12.92 years). 72.3% of patients were found to have
localized disease, and 27.7% had primary metastases.
Good clinical response to induction therapy was ob-
served in 55%, and 73% of patients showed good histo-
logical response. The event-free survival was 0.77 at 1
year and 0.50 at 3 years (n = 44). Conclusion: ET are rare
in patients over the age of 40 years. With adequate mul-
timodal therapy, the results in terms of survival are com-
parable to those in adolescence. Specific age-adapted
treatment regimens are not established. Patients should
be enrolled in international trials, and if necessary treat-
ment should be adjusted for lower tolerance and co-mor-
bidity. 
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Introduction
Ewing’s tumor (ET) is the second most common osseous
tumor of childhood, adolescence, and young adulthood [1, 2].
A new era of ET diagnosis and research was opened in the
mid 1990s when the tumor-specific fusion gene EWS/Fli1 was
described which allows precise allocation of bone and soft tis-
sue sarcomas [3] to the ET family [4]. The introduction of a
multimodal treatment concept consisting of combination
chemotherapy and local therapy modalities, including surgery
and radiation, achieved 60–70% overall survival in patients
with localized disease [2, 5–14]. The majority of clinical trials
accepted pediatric and adolescent patients, with a median 
reported age of < 15 years [8, 15–17]. Information on ET in 
patients over the age of 40 years is scarce.
EICESS 92, a joint trial of the UK Children’s Cancer and
Leukaemia Group (CCLG) and the German Society of Pedi-
atric Oncology and Hematology (Gesellschaft für Pädiatrische
Onkologie und Hämatologie, GPOH) was the first trial open
for patients up to age 35, and the international trial EURO-
E.W.I.N.G. 99 accepts patients up to age 50 years. Moreover, in
both of these studies, the trial center in Münster, Germany,
registered and followed up patients > 50 years as non-study
patients, and collected relevant data from this group. The pre-
sent report gives a brief summary of the disease presentation,
treatment, and outcome in such patients allocated to an ap-
propriate protocol treatment on an intent-to-treat basis.
Patients and Methods
Patient Characteristics
A total of 47 patients over age 40 with newly diagnosed ET, enrolled be-
tween August 1992 and February 2005, were identified among a cohort of
1,720 patients registered at the GPOH Ewing trial center in Münster, Ger-
many. The median age at diagnosis was 47.7 years (range, 40–68.6 years);
20 (42.6%) patients were females, 27 (57.4%), males. The median follow-
up was 2.23 years from diagnosis (range, 0.35–12.92 years) (table 1).
Treatment
Sixteen patients were treated according to EICESS 92, and 31 patients
according to EURO-E.W.I.N.G. 99. Patients gave written informed con-
sent according to institutional and national guidelines. The trials had been
approved by the appropriate ethics committees. Sixteen patients qualified
as regular study patients of EURO-E.W.I.N.G. 99; all other patients were
registered as follow-up patients (table 1). The major reasons for exclusion
from regular study patient status were registration or start of treatment 
> 45 days after biopsy, more than 1 course of other chemotherapy, and age
> 50 years (EICESS 92: age > 35 years). Local treatment consisted of ra-
diotherapy and surgery, and was individually planned for each patient. 
The EICESS 92 protocol accomplished 2 parallel risk-adapted random-
ized trials. Risk groups were defined by disease stage and tumor volume.
Patients with localized tumors < 100 ml were stratified into the standard
risk group, those with tumors > 100 ml and/or metastatic disease were al-
located to the high risk group. All of the patients received a 4-drug induc-
tion treatment of ifosfamide, vincristine, doxorubicin, and actinomycin D
(VAIA). For consolidation treatment, either VAIA or VACA (cyclophos-
phamide replacing ifosfamide) was randomly allocated to standard risk
Table 1. Patient characteristics
EICESS, n (%)
Study patients 0 (0)
Follow-up patients 16 (100)
Total 16 (100)
EURO-E.W.I.N.G. 99, n (%)
Study patients 16 (52)
Follow-up patients 15 (48)
Total 31 (100)
Sex, n (%)
Male 27 (57.4)
Female 20 (42.6)
Age at diagnosis, years, median (range) 47.7 (40–68.6)
Primary tumor site, n (%)
Head/neck 5 (10.6)
Upper extremity 3 (6.4)
Chest 9 (19.2)
Spinal column 4 (8.5)
Abdomen 3 (6.4)
Pelvis 12 (25.5)
Lower extremity 11 (23.4)
Primary tumor type, n (%)
Osseous 32 (68.1)
Extra-osseous 15 (31.9)
Primary tumor volume, ml, median (range) 185 (1–2,836)
Extent of disease, n (%)
Localized 34 (72.3)
Metastases 13 (27.7)
Lung 8
Bone 5
Bone marrow 1
Lymph nodes 3
Other 4
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Fig. 1. EICESS 92 treatment strategy.
patients. In the high risk arm, VAIA treatment was randomized against
EVAIA with the addition of etoposide (E) [18, 19] (fig. 1).
The EURO-E.W.I.N.G. 99 protocol employs vincristine, ifosfamide, dox-
orubicin, and etoposide (VIDE) induction chemotherapy, followed by
risk-adapted randomized treatment [20]. Patients are stratified into risk
groups according to prognostic factors including treatment-independent
parameter such as presence and site of metastases, discriminating between
pulmonary and extrapulmonary, metastases. In localized disease, the vol-
ume of the primary tumor, with a 200-ml cut-off, and/or histological re-
sponse to induction chemotherapy are critical factors for stratification
into the standard or high risk group. Standard risk patients (R 1) are ran-
domized for consolidation treatment with either vincristine, actinomycin
D, and ifosfamide (VAI) or vincristine, actinomycin D, and cyclophos-
phamide (VAC). High risk patients (R 2) are randomized for high dose
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busulfan/melphalan (Bu-Mel) versus VAI. Patients with extra-pulmonary
metastatic disease (R 3) are not randomized, but high dose chemotherapy
using Bu-Mel, treosulfan-Mel, or tandem Mel-E followed by autologous
stem cell reinfusion or participation in a phase II study is recommended.
The EURO-E.W.I.N.G. 99 trial is ongoing and still recruiting patients
(fig. 2). 
In the EICESS 92 trial, preoperative radiotherapy was frequently used
[18]. The EURO-E.W.I.N.G. 99 protocol, however, based on a growing
awareness of the prognostic impact of histological response, recommends
preoperative radiotherapy only to avoid intralesional surgery, e.g. in the
case of poor clinical response to chemotherapy [21–23]. Surgery was
recommended for all patients, if feasible. 
Statistical Analysis
Statistical analyses were performed using the SPSS Statistical Package
14.02 (SPSS Inc., Chicago, IL, USA) and SAS 9.1.3. (SAS Institute Inc,
Cary, NC, USA). Distributions of survival curves/times (including event-
free survival (EFS) and overall survival (OS)) were estimated by the Ka-
plan-Meier method. Survival time starts at the day of diagnosis and ends
at the date of first event (EFS) or death (OS) or the date of the patient’s
most recent consultation when all living patients (OS) and patients with-
out event (EFS) were censored. An event was defined as relapse (local or
metastatic), progression under therapy (assessable tumor growth), sec-
ondary malignancy, or death [24]. Group comparisons were calculated
using the log-rank statistic [25–27]. Multivariate analyses were performed
by Cox’s proportional hazard method [28]. The significance level was set
at p < 0.05 for two-sided test. No alpha corrections were done for multiple
testing.
Results
Baseline Characteristics of the Study Population
Patient characteristics are given in table 1. The histopatholog-
ical diagnosis was Ewing’s sarcoma (including atypical
Ewing’s sarcoma) in 31 patients (66%), and peripheral primi-
tive neuroectodermal tumor (PNET) in 16 patients. Similar to
the observations in younger patients, this difference in histol-
ogy was of no prognostic value (data not shown). ET of the
bone was diagnosed in 32 patients (68.1%), extraosseous ET
in 15 (31.9%). The prevalent primary tumor site was the pelvis
in 12 patients (25.5%), followed by the lower extremities in 11
(23.4%), and the thoracopulmonary region in 9 (19.2%). ET
of the spine was observed in 4 patients (8.5%), of the head
and neck in 5 (10.6%), and of the upper extremity and the ab-
domen in 3 patients each (6.4 and 6.4%). The median tumor
volume was 185 ml (range, 1–2,836 ml). A large tumor volume,
with a 100-ml cut-off in EICESS 92 and a 200-ml cut-off in
EURO-E.W.I.N.G. 99, was described in 10 patients (71.4%)
from EICESS 92 and 14 patients (50%) from EURO-
E.W.I.N.G. 99. In 5 patients, the tumor volume could not 
be determined. Thirty-four patients (72.3%) had localized
 disease, and 13 patients (27.7%) had metastases at the time of
diagnosis.
Treatment
Sixteen patients were treated according to the EICESS 92
protocol. Five patients (35.7%) were stratified into the stan-
dard arm. Three patients received the VAIA+VACA combi-
nation. One out of 3 completed treatment according to proto-
col, i.e. 4 cycles of VAIA followed by 10 cycles of VACA. One
patient received 4 times VAIA and 5 times VACA, and in 
1 patient there was no detailed information about the number
of cycles. Two patients had the VAIA+VAIA combination,
one of them completing according to protocol with 4 plus 10
cycles of VAIA, and the other one completing 5 times VAIA.
Nine patients (64.3%) were stratified into the high risk arm.
Seven patients received EVAIA. Two out of 7 had 14 cycles
according to protocol. Two patients received 10 cycles of
EVAIA, 1 patient had 4 cycles, 1 patient 5 cycles of EVAIA
followed by 2 times VAIA, and of 1 patient there was no de-
tailed information about the number of cycles. Two patients
had VAIA, with 1 patient completing 5 cycles and information
unavailable in the other. Two of the 9 patients stratified into
the high risk group additionally received a Bu-Mel high dose
regimen off protocol. In 2 patients, no detailed information
was provided on risk stratification and chemotherapy.
In EURO-E.W.I.N.G. 99, data on induction treatment were
available in 30 patients. Twenty-three patients completed 6 cy-
cles of VIDE induction, 3 patients received at least 4 cycles of
VIDE induction, and 1 patient each had 3, 5, 7, and 14 cycles;
in 1 patient the number of cycles was not documented. For
consolidation treatment, 12 of the EURO-E.W.I.N.G. 99 pa-
tients over 40 years received VAI, 4 had VAC, and 8 patients
were given a high dose regimen with autologous stem cell re-
infusion, including 6 who received Bu-Mel and 1 with tandem
Mel-E. One patient was treated off protocol with high dose
etoposide/carboplatin/ifosfamide (ICE) (table 2).
Toxicity
Toxicity was graded according to modified National Institute
of Health Common Toxicity Criteria (NIH CTC). In EICESS
92, grade 3 or 4 neutropenia was seen in 23 of 126 reported
EVAIA cycles, and 4 of 98 reported VAIA cycles, thrombocy-
topenia in 18/126 EVAIA cycles, mucositis and nau-
sea/vomiting in 5/98 VAIA cycles (table 3). Regarding VIDE
induction, grade 3 or 4 neutropenia was observed in 89 of 178
reported cycles, thrombocytopenia in 54/178, and anemia in
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Fig. 2. EURO-E.W.I.N.G .99 treatment strategy.
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VIDE cycles, i.e. 3 times due to delayed hematological recov-
ery, once due to intercurrent local treatment, and 6 times for
other reasons, mainly patient’s choice. 
The VIDE cycle series was incomplete in 5 patients. The rea-
sons given were patient’s choice in 1 patient, death for
 unknown reason in 1 patient, local treatment after 4 cycles in 
1 patient, and unknown reasons in 2 patients. No treatment
delays were reported for VAI or VAC consolidation.
Local Treatment
Data on local treatment were available in 42 patients (table 5).
Ten patients (23.8%) received surgery alone, 7 patients
(16.7%) definitive radiotherapy, and 22 patients (52.4%) com-
bined modality treatment. Three patients had no local therapy
of the primary tumor (7.1%). Wide margins were achieved in
18 patients (69.2%), resection was marginal in 4 patients
(15.4%), and tumor removal was incomplete in 4 patients
(15.4%). In 6 patients, no information on surgical margins was
available. All patients with marginal or intralesional resection
received additional radiotherapy. Three-year EFS in this
group was 0.38 (95% confidence interval (CI) 0.09–0.67) com-
pared to 0.53 (95% CI 0.35–0.68) in patients with wide surgical
margins (p = 0.2963).
Clinical and Pathological Response
Clinical response of the primary tumor was assessed after 
2 cycles of induction chemotherapy in patients with no prima-
ry surgery. Twenty patients were evaluated for response to
chemotherapy. Complete or partial response with > 50% re-
duction in tumor volume was noted in 11 patients (55%).
Table 2. Chemotherapy
Study Chemotherapy Patients, n
EICESS 92 4 VAIA + 10 VAIA or 10 VACA 16
Standard risk EVAIA 5
High risk VAIA 9
High risk, off protocol HD Bu-Mela 7
no information 2
EURO-E.W.I.N.G. 99 induction 2
VIDE 31
6 cycles 30
not according to protocol 25
14 cycles 1
7 cycles 1
5 cycles 1
4 cycles 3
3 cycles 1
no information 1
consolidation: 24
VAI 12
VAC 4
HD Bu-Mel 6
HD Double ME 1
ICEa 1
none 5
aBu-Mel and ICE non-protocol treatment.
VAIA = vincristine, adriamycin, ifosfamide, actinomycin D; VACA = vin-
cristine, adriamycin, cyclophosphamide, actinomycin D; E = etoposide;
VIDE = vincristine, ifosfamide, doxorubicin, etoposide; VAI = vincristine,
actinomycin D, ifosfamide; VAC = vincristine, actinomycin D, cyclophos-
phamide; HD = high dose chemotherapy with autologous stem cell rein-
fusion, Bu-Mel = busulfan-melphalan, Double ME = tandem high dose
melphalan-etoposide; ICE = etoposide, carboplatin, ifosfamide.
Local therapy Patients, n (%)
Total number of patients 42 (100)
Surgery 10 (23.8)
Surgery alone 18 (69.2)
Type of surgery 4 (15.4)
Radical and wide 4 (15.4)
Marginal compartmental
Intralesional
Radiotherapy 7 (16.7)
Surgery plus radiotherapy 22 (52.4)
Local treatment 3 (7.1)
Table 5. Local treat-
ment modalities
Table 6. Histopathological response to chemotherapy according to the
criteria of Salzer-Kuntschik [29]
Histopathological response to chemotherapy Patients, n (%)
Good (< 10% viable tumor cells) 11 (73)
Poor (≥ 10% viable tumor cells) 4 (27)
Response assessment available 15 (32)
Response assessment not done 32 (68)
22/178. As to consolidation chemotherapy, grade 3 or 4 
neutropenia was seen in 28 of 96 VAI, and 12 of 32 VAC cycles
reported. Grade 3 or 4 thrombocytopenia was reported in 6 
of 86 VAI, and 4 of 32 VAC cycles. 
Less frequently observed grade 3 or 4 toxicity under EURO
E.W.I.N.G. 99 treatment included fever, nausea/vomiting, rise
of transaminases, stomatitis, esophagitis, and neurotoxicity.
High dose therapy was generally associated with grade 4
hematotoxicity as expected; 1 patient showed grade 4 veno-
occlusive disease after Bu-Mel, 1 showed grade 4 mucosits,
and in 3 patients no documentation was available (table 4).
No toxicity-related death was observed. 
Treatment Delay
In EICESS 92, treatment delays were reported for 24 cycles,
i.e. 5 times due to previous infection, once due to hematotoxi-
city, 3 times for intercurrent local treatment, once for bladder
dysfunction, and once for port-a-cath replacement; in 13 in-
stances the reason was unknown.
Treatment delay in EURO-E.W.I.N.G. 99, defined as more
than 5 days postponement of a cycle, was reported for 10
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42 patients between 14 and 52 years and 182 patients between
16 and 55 years, respectively.
It is noteworthy that all of the quoted studies in ‘adults’ in-
cluded a large number of patients from the typical age group
of ET patients (average median age 20 years: Sinkovics et al.
[32], median age 21 years (range, 16–36 years); Verill et al. [35],
median age 24 years (range 14–51 years), 31/59 patients
(52.52%) between 15 and 24 years; Fizazi et al. [37], median
age 21.5 years (range, 16–55 years)) rather than focusing on
patients beyond the typical age. As yet, only 1 single institu-
tion report has been published on patients over 40 years. How-
ever, this study was a retrospective analysis covering a wide
time span of 28 years and 6 different treatment protocols, and
evaluated only patients with localized disease [38].
The analysis reported here includes patients with localized
and disseminated disease. Besides, patients were recruited
within a relatively short period of time (1992–2005), which im-
plies fairly homogeneous diagnostic procedures and treat-
ment. All patients were treated according to the international
clinical trials EICESS 92 or EURO-E.W.I.N.G. 99 which were
both open for older patients. 
In large controlled ET trials, parameters such as primary dis-
seminated disease, poor histological response to induction
treatment, large tumor volume and central axial site, and age 
> 14 years have emerged as major unfavorable factors [39–44].
In the present study, 13 out of 47 patients (27.7%) over the
age of 40 years had presented with distant metastases at the
time at diagnosis, which is comparable to data reported else-
where [6, 15, 20, 35, 42–49]. There were also no differences re-
garding tumor site [2, 6, 50, 51] and histopathological response
to induction chemotherapy [33, 35, 52, 53]. However, the group
of patients over the age of 40 did show a rather high number
of large tumors (71.2% of patients from EURO-E.W.I.N.G. 99
and 50% of patients from EICESS 92). Interestingly, this co-
hort also included a high proportion of patients with extra-os-
seous tumors (15 patients, 31.9%). Further investigations are
needed to find out whether or not tumor biology is also differ-
ent in the older age group. It would thus be of major interest
to diagnose and treat such patients in controlled studies. Pa-
tients younger than 40 years showed a 3-year EFS of 0.57
(95% CI 0.53–0.59) and 3-year OS of 0.68 (95% CI 0.66–0.70).
Thus, patients over 40 had a slightly but not significantly lower
survival probability (p = 0.1520; p = 0.1314).
Chemotherapy-related toxicity is substantial, but predictable
and manageable. Most importantly, there were only very few
toxicity-related treatment delays, which is in agreement with
previously published data [54]. In conclusion, treatment of ET
patients over the age of 40 years – similar to that given in the
younger age group – should provide for a multimodal treat-
ment concept including combination chemotherapy, complete
surgical resection wherever possible, and more radiotherapy.
The outcome of our study population is quite comparable to
the outcome of pediatric patients and adolescents although
the feasibility of applying intense chemotherapy regimes may
Histopathological response was determined in 15 patients 
according to the method of Salzer-Kuntschik et al. [29].
Eleven patients (73%) achieved good histopathological re-
sponse (< 10% viable tumor cells), 4 patients (27%) were
graded as poor responders with more than 10% viable tumor
cells (table 6). 
Survival
Figure 3 shows EFS and OS. The median time from diagnosis
to last follow-up or death was 2.23 years (range, 0.35–12.92
years). EFS after 3 years was 0.50 (95% CI 0.34–0.64), and OS
was 0.60 (95% CI 0.43–0.73). 3-year-EFS was 0.56 (0.67) in pa-
tients with localized disease, and 0.35 (0.43) in those with pri-
mary dissemination. In order to better classify these results in
patients over the age of 40, we compared them with data ob-
tained from 1,591 patients under 40 from EICESS 92 and
EURO-E.W.I.N.G. 99. By comparison, 1,591 patients under 40
from EICESS 92 and EURO-E.W.I.N.G. 99 showed a 3-year
EFS of 0.57 (95% CI 0.54–0.59) and 3-year OS of 0.68 (95%
CI 0.66–0.70). Thus, patients over 40 had a slightly but not sig-
nificantly lower survival probability (p = 0.1520; p = 0.1314). If
adjusted for metastases at diagnosis and study affiliation, the
event risk was 1.33 (95% CI 0.89–2) for older compared to
younger patients (p = 0.1685).
Discussion
Clinical presentation, treatment modalities, and outcome were
analyzed in 47 patients over age 40 diagnosed of ET. ET above
age 40 are extremely rare, which is why the majority of analy-
ses concerning treatment, prognostic factors, and outcome
focus on pediatric patients, adolescents, and young adults
[15–17; 30, 31]. There are only few data and reports available
on ET in the older age group, and these refer to ages 16–36
[32, 33], 17–50 [34–36], and 16–55 years [37]. Four of these
publications (Picci et al. [33], Siegel et al. [34], Sinkovics et al.
[32], Klassen et al. [36]) reported an unfavorable prognosis for
adults with non-metastatic ET compared with patients diag-
nosed in childhood. By contrast, Verill et al. [35] and Fizazi et
al. [37] showed outcomes similar to those seen in children in
time from diagnosis (years)
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tyFig. 3. Three-year
event-free survival
(EFS) and overall
survival (OS) in 
patients with Ewing’s
tumor diagnosed
over the age of 
40 years (n = 44).
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have been restricted in a fair number of patients. Age under
these circumstances is not a major poor prognostic feature [35,
37] – the unfavorable prognostic factors in the older age group
seem similar to those seen in younger patients [39–44]. Treat-
ment according to the studies designed for younger patients is
feasible and effective. It is therefore recommended to enroll
older patients into the ongoing Ewing trials. The trial office
offers the support of a multidisciplinary team in guiding a pa-
tient through the entire treatment for optimal results. This will
also help to augment the knowledge on this age group and
eventually develop age-adapted treatment concepts.
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